190 related articles for article (PubMed ID: 30352285)
21. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Respir Care; 2002 Jul; 47(7):818-22. PubMed ID: 12088552
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
[TBL] [Abstract][Full Text] [Related]
23. The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation.
Fraňová S; Kazimierová I; Pappová L; Molitorisová M; Jošková M; Šutovská M
Pulm Pharmacol Ther; 2019 Feb; 54():60-67. PubMed ID: 30502381
[TBL] [Abstract][Full Text] [Related]
24. The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils.
Dal Sasso M; Bovio C; Culici M; Fonti E; Braga PC
Drugs Exp Clin Res; 2002; 28(4):147-54. PubMed ID: 12512232
[TBL] [Abstract][Full Text] [Related]
25. [Novel approach to respiratory pharmacology--pharmacological basis of cough, sputum and airway clearance].
Miyata T
Yakugaku Zasshi; 2003 Dec; 123(12):987-1006. PubMed ID: 14689863
[TBL] [Abstract][Full Text] [Related]
26. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
Pulm Pharmacol Ther; 2018 Feb; 48():185-194. PubMed ID: 29233650
[TBL] [Abstract][Full Text] [Related]
27. Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.
Hurt K; Bilton D
Respiration; 2014; 88(6):441-8. PubMed ID: 25472021
[TBL] [Abstract][Full Text] [Related]
28. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
[TBL] [Abstract][Full Text] [Related]
29. [ Erdosteine (Mucodox), oral administration].
J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
[No Abstract] [Full Text] [Related]
30. Evaluating the efficacy of mucoactive aerosol therapy.
Fuloria M; Rubin BK
Respir Care; 2000 Jul; 45(7):868-73. PubMed ID: 10926385
[TBL] [Abstract][Full Text] [Related]
31. [Mucolytics in acute and chronic respiratory tract disorders. I. Pathophysiology and mechanisms of action].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):245-7. PubMed ID: 12053600
[TBL] [Abstract][Full Text] [Related]
32. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.
Marchioni CF; Moretti M; Muratori M; Casadei MC; Guerzoni P; Scuri R; Fregnan GB
Lung; 1990; 168(5):285-93. PubMed ID: 2126836
[TBL] [Abstract][Full Text] [Related]
33. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
34. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
Disse B
Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
[TBL] [Abstract][Full Text] [Related]
36. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.
Ricevuti G; Mazzone A; Uccelli E; Gazzani G; Fregnan GB
Thorax; 1988 Aug; 43(8):585-90. PubMed ID: 3051508
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological approaches to discovery and development of new mucolytic agents.
King M; Rubin BK
Adv Drug Deliv Rev; 2002 Dec; 54(11):1475-90. PubMed ID: 12458156
[TBL] [Abstract][Full Text] [Related]
38. Pemphigus herpetiformis-type drug reaction caused by erdosteine containing mucolytic in a child.
Akoglu G; Yavuz SO
Cutan Ocul Toxicol; 2017 Sep; 36(3):302-304. PubMed ID: 27881029
[TBL] [Abstract][Full Text] [Related]
39. Aerosol Medications for Treatment of Mucus Clearance Disorders.
Rubin BK
Respir Care; 2015 Jun; 60(6):825-9; discussion 830-32. PubMed ID: 26070577
[TBL] [Abstract][Full Text] [Related]
40. Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.
Yan X; Song Y; Shen C; Xu W; Chen L; Zhang J; Liu H; Huang M; Lai G; Qian G; Wang J; Ye X; Zheng J; Bai C
Int J Chron Obstruct Pulmon Dis; 2017; 12():803-812. PubMed ID: 28405161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
